Free Radical Biology and Medicine, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Ageing Research Reviews, Год журнала: 2023, Номер 89, С. 101979 - 101979
Опубликована: Июнь 15, 2023
Therapeutic strategies for neurodegenerative disorders have commonly targeted individual aspects of the disease pathogenesis to little success. Neurodegenerative diseases, including Alzheimer's (AD) and Parkinson's (PD), are characterized by several pathological features. In AD PD, there is an abnormal accumulation toxic proteins, increased inflammation, decreased synaptic function, neuronal loss, astrocyte activation, perhaps a state insulin resistance. Epidemiological evidence has revealed link between AD/PD type 2 diabetes mellitus, with these sharing some commonalities. Such opened up promising avenue repurposing antidiabetic agents in treatment disorders. A successful therapeutic strategy would likely require single or which target separate processes disease. Targeting cerebral signalling produces numerous neuroprotective effects preclinical brain models. Clinical trials shown promise approved diabetic compounds improving motor symptoms PD preventing decline, further phase II III underway populations. Alongside signalling, targeting incretin receptors represents one most currently available AD/PD. Most notably, glucagon-like-peptide-1 (GLP-1) receptor agonists displayed impressive clinical potential early studies. GLP-1 agonist, liraglutide, been demonstrated improve glucose metabolism functional connectivity small-scale pilot trials. Whilst agonist exenatide effective restoring function cognition. reduces inhibits apoptosis, prevents protein aggregation, enhances long-term potentiation autophagy as well restores dysfunctional signalling. Support also increasing use additional treatments, intranasal insulin, metformin hydrochloride, peroxisome proliferator-activated nuclear γ agonists, amylin analogs, tyrosine phosphatase 1B inhibitors investigation deployment treatment. As such, we provide comprehensive review anti-diabetic PD.
Язык: Английский
Процитировано
86
Ageing Research Reviews, Год журнала: 2024, Номер 96, С. 102255 - 102255
Опубликована: Март 14, 2024
Язык: Английский
Процитировано
31
International Immunopharmacology, Год журнала: 2023, Номер 119, С. 110239 - 110239
Опубликована: Май 1, 2023
Язык: Английский
Процитировано
24
Inflammopharmacology, Год журнала: 2024, Номер 32(2), С. 1091 - 1112
Опубликована: Янв. 31, 2024
Abstract Erigeron bonariensis is widely distributed throughout the world's tropics and subtropics. In folk medicine, E. has historically been used to treat head brain diseases. Alzheimer’s disease (AD) most widespread form of dementia initiated via disturbances in function. Herein, neuroprotective effect chemically characterized ethanolic extract reported for first time an AD animal model. Chemical profiling was conducted using UPLC–ESI-MS analysis. Female rats underwent ovariectomy (OVX) followed by 42 days D-galactose (D-Gal) administration (150 mg/kg/day, i.p) induce AD. The OVX/D-Gal-subjected received either donepezil (5 mg/kg/day) or at 50, 100, 200 given 1 h prior D-Gal. analysis identified chemicals, including flavonoids, phenolic acids, terpenes, nitrogenous constituents. Several metabolites, such as isoschaftoside, casticin, velutin, pantothenic acid, xanthurenic C18-sphingosine, linoleamide, erucamide, were herein genus. Treatment with mitigated cognitive decline Morris Water Maze test histopathological alterations cortical hippocampal tissues rats. Moreover, OVX/D-Gal-induced Aβ aggregation, Tau hyperphosphorylation, AChE activity, neuroinflammation (NF-κBp65, TNF-α, IL-1β), apoptosis (Cytc, BAX). Additionally, ameliorated increasing α7-nAChRs expression, down-regulating GSK-3β FOXO3a modulating Jak2/STAT3/NF-ĸB p65 PI3K/AKT signaling cascades. These findings demonstrate memory-enhancing effects OVX/D-Gal rat model, highlighting its potential a promising candidate management. Graphical
Язык: Английский
Процитировано
10
Life Sciences, Год журнала: 2024, Номер 355, С. 123001 - 123001
Опубликована: Авг. 22, 2024
Язык: Английский
Процитировано
10
Phytotherapy Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 9, 2025
ABSTRACT Metabolic syndrome (MetS) is a cluster of interrelated metabolic abnormalities that significantly elevate the risk cardiovascular disease, obesity, and diabetes. Flavonoids, diverse class bioactive polyphenolic compounds found in plant‐derived foods beverages, have garnered increasing attention as potential therapeutic agents for improving health. This review provides comprehensive analysis effects flavonoids context MetS, with particular focus on their modulation AMP‐activated protein kinase (AMPK) pathway. AMPK serves central regulator cellular energy balance, glucose metabolism, lipid homeostasis, making it critical target intervention. Through systematic literature up to April 2024, preclinical studies across various flavonoid subclasses, including flavonols, flavan‐3‐ols, were analysed elucidate mechanistic roles regulation. Many suggests enhance glycolipid metabolism by facilitating transporter 4 (GLUT4) translocation activating pathway, thereby glycemic control diabetes models. In obesity‐related studies, demonstrated significant inhibitory synthesis, reduced adipogenesis, attenuated proinflammatory cytokine secretion via activation. These findings show broad addressing MetS its associated disorders. While these insights highlight promising natural health improvement, important note excessive concentrations may disrupt pathways, potentially leading imbalance cytotoxicity. Further clinical trials are essential determine optimal dosing regimens, formulations, long‐term safety efficacy flavonoids. highlights importance interventions targeting comorbidities, offering foundation future translational research.
Язык: Английский
Процитировано
2
European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177305 - 177305
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
2
Pharmaceuticals, Год журнала: 2023, Номер 16(5), С. 753 - 753
Опубликована: Май 16, 2023
Alzheimer's disease (AD) is a progressive neurological illness characterized by memory loss and cognitive deterioration. Dapagliflozin was suggested to attenuate the impairment associated with AD; however, its mechanisms were not fully elucidated. This study aims examine possible of neuroprotective effects dapagliflozin against aluminum chloride (AlCl3)-induced AD. Rats distributed into four groups: group 1 received saline, 2 AlCl3 (70 mg/kg) daily for 9 weeks, groups 3 4 administered 5 weeks. (1 (5 then given another Two behavioral experiments performed: Morris Water Maze (MWM) Y-maze spontaneous alternation (Y-maze) task. Histopathological alterations in brain, as well changes acetylcholinesterase (AChE) amyloid β (Aβ) peptide activities oxidative stress (OS) markers, all evaluated. A western blot analysis used detection phosphorylated 5' AMP-activated protein kinase (p-AMPK), mammalian target Rapamycin (p-mTOR) heme oxygenase-1 (HO-1). Tissue samples collected isolation glucose transporters (GLUTs) glycolytic enzymes using PCR analysis, brain levels also measured. The current data demonstrate that represents approach combat AlCl3-induced AD rats through inhibiting stress, enhancing metabolism activating AMPK signaling.
Язык: Английский
Процитировано
20
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(14), С. 11450 - 11450
Опубликована: Июль 14, 2023
Insulin resistance as a hallmark of type 2 DM (T2DM) plays role in dementia by promoting pathological lesions or enhancing the vulnerability brain. Numerous studies related to insulin/insulin-like growth factor 1 (IGF-1) signaling are linked with various types dementia. Brain insulin is disturbances Aβ production and clearance, Tau hyperphosphorylation, microglial activation causing increased neuroinflammation, breakdown tight junctions blood-brain barrier (BBB). These mechanisms have been studied primarily Alzheimer's disease (AD), but research on other forms like vascular (VaD), Lewy body (LBD), frontotemporal (FTD) has also explored overlapping mechanisms. Researchers currently trying repurpose anti-diabetic drugs treat dementia, which dominated sensitizers substrates. Although it seems promising feasible, none trials succeeded ameliorating cognitive decline late-onset We highlight possibility repositioning strategy for therapy reflecting current previous clinical trials. describe molecular perspectives through insulin/IGF-1 pathway.
Язык: Английский
Процитировано
18
Cellular Signalling, Год журнала: 2024, Номер 122, С. 111311 - 111311
Опубликована: Июль 24, 2024
Язык: Английский
Процитировано
9